Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

d therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, successfully concluded a Phase I clinical program. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, expected to enter Phase II clinical development in the first quarter of 2010 for the treatment of type 2 diabetes mellitus, and CCX354, a CCR1 antagonist expected to enter Phase II by year end for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumpt
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... 2015 Nihon University is pleased to ... Medical-Engineering Collaboration "Medicine Definitely Jumps Up with 8K" ... Tokyo, Japan . Many experts ... will present their achievements and future prospects on ... produced with 8K technology. (Documentation: ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
(Date:7/3/2015)... 2015 According to a ... Rhythm Management Market ECG, Implantable Loop Recorder, Manual ... Defibrillator, Dual Chamber Pacemaker, CRT-D, CRT-P - Global ... Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) ... by 2020 from $21,137.7 Million in 2015, at ...
Breaking Medicine Technology:Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4
... IRIDEX Corporation (Nasdaq: IRIX ) announced ... introducing an optional MicroPulse module in the Company,s IQ532 ... of infrared, yellow and green laser systems which can ... delivering a green wavelength have been our highest selling ...
... announces that a new market research report is ... Aesthetic Lasers and Energy Devices - Global Market ... http://www.reportlinker.com/p0575304/Aesthetic-Lasers-and-Energy-Devices---Global-Market-Briefing-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Beauty_Salon_and_Services Aesthetic Lasers and Energy ... Summary GlobalData,s new ...
Cached Medicine Technology:IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market 2IRIDEX Launches New MicroPulse™ Module Targeting the Broad Ophthalmology Laser Photocoagulation Market 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 2Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 3Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 4Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 5Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 6Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 7Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 8Aesthetic Lasers and Energy Devices - Global Market Briefing to 2017 9
(Date:7/5/2015)... (PRWEB) , ... July 05, 2015 , ... Women’s ... and college) at their Lake Orion location. The special consists of 2 months of ... in Wellness, powered by Movestrong is located at 1410 South Lapeer Road in Lake ...
(Date:7/4/2015)... ... July 04, 2015 , ... Chronic Neck Pain. Neck ... sufferers have pain located in the neck. Another 19% suffer from head, migraine, or ... literature suggests that 45% of American workers must deal with neck pain. ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... enrollment on July 2nd creating a buzz of media attention. In an effort ... online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling overwhelmed ...
(Date:7/3/2015)... ... ... rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , has ... from March 4th - 6th, the 2016 (a previous announcement had stated the dates ... take participants from the basic training and fundamentals of nasal surgery through the most ...
(Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
Breaking Medicine News(10 mins):Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
... to minimise the risk of surface contamination in washrooms caused by the ... ... 2009 -- Did you know that flushing toilets ,sneeze, dirty water and ... bacteria such as E coli and risking the health and safety of ...
... The American College of Medical Genetics (ACMG) has joined ... Pathologists, and the American Society for Clinical Pathology in ... human genes associated with breast and ovarian cancer interfere ... regarding their health care. The lawsuit challenges patents on ...
... Inc. (Nasdaq: AHPI ) reported that its net ... from about $100,000, or 1 cent per share, in the ... a negative 6 cents per share, due to lower sales.Net ... $1.5 million, to about $12.4 million. Sales fell in ...
... With today,s release of the annual Social ... the nation,s two largest programs are on a ... to work together on reforms of both programs ... will need to recognize the underlying structural factors ...
... According to Latest Projections WASHINGTON , May 12 ... issued earlier today highlight the imperative to act immediately ... according to the American Academy of Actuaries . ... deteriorated further during the past year and inaction will ...
... 12 BioMed Realty Trust, Inc. (NYSE: BMR ... 14,000,000 shares of its common stock pursuant to an effective ... BioMed expects to use the net proceeds of the ... its $600.0 million unsecured line of credit and for other ...
Cached Medicine News:Health News:Pink Hygiene Issue Toilet Sneeze Warning for Workplaces 2Health News:ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics 2Health News:ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics 3Health News:Allied Healthcare Posts Third Quarter Loss 2Health News:Allied Healthcare Posts Third Quarter Loss 3Health News:Allied Healthcare Posts Third Quarter Loss 4Health News:Allied Healthcare Posts Third Quarter Loss 5Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 3Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 2Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 3
... Microline Small Bone Power System combines ... performing under the most exacting conditions. ... for small bone osteotomies and oral/maxillofacial ... (extended length available), oscillating saw (extended ...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... System incorporates specially designed metal tubes that ... in a minimally invasive manner. These tubes, ... 5.3 mm to 20.8 mm. The METRx ... one around the other - through the ...
The Telescopic Plate Spacer (TPS - C) Implants is an expandable titanium spacer designed to stabilize the spine following corpectomy/ vertebrectomy procedures....
Medicine Products: